How Will the Market React to Achilles Therapeutics PLC (ACHL) Stock Getting a Bullish Rating

The market has been high on Achilles Therapeutics PLC (ACHL) stock recently. ACHL gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Achilles Therapeutics PLC has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ACHL!

See Full ACHL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ACHL Stock Today?

Achilles Therapeutics PLC (ACHL) stock has risen 0.84% while the S&P 500 is lower by -0.06% as of 1:20 PM on Wednesday, Mar 20. ACHL has gained $0.01 from the previous closing price of $1.19 on volume of 284,142 shares. Over the past year the S&P 500 has gained 30.97% while ACHL has gained 36.36%. ACHL lost -$1.89 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Achilles Therapeutics PLC click here.

More About Achilles Therapeutics PLC

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma. Click Here to get the full Stock Report for Achilles Therapeutics PLC stock.